Compare AVX & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVX | TVGN |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 21.3M |
| IPO Year | 2020 | 2021 |
| Metric | AVX | TVGN |
|---|---|---|
| Price | $3.65 | $6.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.7K | 9.3K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,340,811.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $0.14 |
| 52 Week High | $6.40 | $12.03 |
| Indicator | AVX | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 57.35 |
| Support Level | $0.50 | $6.22 |
| Resistance Level | $3.92 | $7.42 |
| Average True Range (ATR) | 0.35 | 0.47 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 72.88 | 90.91 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.